Lantern Pharma CEO Explains How Zeta AI Could Revolutionize Cancer Drug Discovery
Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma discusses the company’s new Zeta autonomous computational biology platform and how it could dramatically accelerate cancer drug discovery. Designed to perform expert-level bioinformatics, statistical analysis, and computational biology, Zeta can analyze massive biological datasets, identify meaningful correlations, and help researchers avoid flawed analyses—all through natural language interaction.
Sharma explains how Zeta can reduce months of complex computational research to minutes while helping scientists validate drug candidates, discover new therapeutic combinations, and improve research accuracy. Rather than replacing scientists, the platform is designed to automate time-consuming data analysis so researchers can focus on scientific discovery, potentially accelerating the development of new cancer treatments and improving outcomes for patients.
#LanternPharma
#LTRN
#ArtificialIntelligence
#AI
#ComputationalBiology
#Bioinformatics
#CancerResearch
#DrugDiscovery
#PrecisionMedicine
#Biotechnology
#MachineLearning
#HealthcareInnovation
#NASDAQ
#JaneKing
#NewsOut
